Hsbc Holdings PLC Allakos Inc. Transaction History

Hsbc Holdings PLC

$168 Billion
Q3 2024

A detailed history of Hsbc Holdings PLC transactions in Allakos Inc. stock. As of the latest transaction made, Hsbc Holdings PLC holds 28,243 shares of ALLK stock, worth $29,937. This represents 0.0% of its overall portfolio holdings.

Number of Shares

28,243

Previous 35,830 21.17%

Holding current value

$29,937

Previous $35,000 48.57%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$0.54 - $0.92 $4,096 - $6,980	-7,587 Reduced 21.17%	28,243 $18,000
Q1 2024 May 15, 2024	BUY	$1.02 - $3.23 $7,725 - $24,464	7,574 Added 26.8%	35,830 $45,000
Q4 2023 Feb 12, 2024	BUY	$1.72 - $3.18 $20,617 - $38,118	11,987 Added 73.68%	28,256 $77,000
Q3 2023 Nov 13, 2023	SELL	$2.13 - $5.55 $6,737 - $17,554	-3,163 Reduced 16.28%	16,269 $36,000
Q2 2023 Aug 11, 2023	BUY	$3.6 - $5.25 $3,175 - $4,630	882 Added 4.75%	19,432 $84,000
Q1 2023 May 15, 2023	SELL	$4.3 - $8.27 $22,725 - $43,706	-5,285 Reduced 22.17%	18,550 $82,000
Q4 2022 Feb 14, 2023	SELL	$5.66 - $8.42 $180,995 - $269,254	-31,978 Reduced 57.29%	23,835 $200,000
Q2 2022 Aug 11, 2022	BUY	$2.6 - $6.14 $145,113 - $342,691	55,813 New	55,813 $178,000
Q1 2021 May 14, 2021	SELL	$109.73 - $153.66 $253,476 - $354,954	-2,310 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$79.58 - $152.45 $183,829 - $352,159	2,310 New	2,310 $323,000
Q1 2020 May 15, 2020	SELL	$44.49 - $93.39 $110,290 - $231,513	-2,479 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$66.49 - $137.73 $164,828 - $341,432	2,479 New	2,479 $238,000

Others Institutions Holding ALLK

# of Institutions

Shares Held

64.7M

Call Options Held

47.1K

Put Options Held

View Full List

About Allakos Inc.

Ticker ALLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,726,096
Market Cap $89.8M
Description
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...

More about ALLK

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Hsbc Holdings PLC, based on Form 13F filings with the SEC.

News

Stay updated on Hsbc Holdings PLC with notifications on news.

Account

Hsbc Holdings PLC Allakos Inc. Transaction History